Skip to main content
SLGL
NASDAQ Life Sciences

Opaleye Management, a 10% owner, adds $2.79M in Sol-Gel shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$69.07
Mkt Cap
$226.233M
52W Low
$21.1
52W High
$97.97
52W Position info
227% above low
Off High info
29% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

SLGL has more than doubled off its 52-week low of $21.1 on elevated volume (2.3× avg).

Summary

10% owner Opaleye Management bought $2.79M of Sol-Gel shares, increasing its position to 525,217 shares.


Key Events · Ownership and Investor Activity · SLGL

  • 10% Owner Adds $2.79M Position

    Opaleye Management bought 40,330 shares for $2,790,326 across five transactions on August 28 and 31, at prices ranging from $68.23 to $71.40.

  • Stake Rises to 525,217 Shares

    Post-transaction holdings reached 525,217 shares, up from 484,887 shares before the purchases.

  • Correction of Erroneous Sale

    10,000 of the shares were purchased to correct an erroneous sale on August 28, 2026; the remaining 30,113 shares were new acquisitions.

  • Follows Q2 Results and Phase 3 Update

    The buying comes after Sol-Gel reported Q2 revenue of $0.6M and a net loss of $3.7M on August 20, and confirmed Phase 3 SGT-610 top-line data is expected in late November.


Analysis · SLGL · Life Sciences

Opaleye Management, a 10% owner, bought $2.79 million of Sol-Gel stock across five transactions on August 28 and 31, lifting its stake to 525,217 shares. The purchase is more than 20 times larger than its prior $125K buy in July and includes a 10,000-share correction of an erroneous sale. The buying comes just days after Sol-Gel reported Q2 results and confirmed its Phase 3 SGT-610 trial remains on track for top-line data in late November.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SLGL was trading at $69.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.2M. The 52-week trading range was $21.10 to $97.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SLGL - Latest Insights

SLGL
Aug 20, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $78.58
Real-time Price: $66.01 info
Change: -$12.57 (-16%) info
Market Cap: $216.117M info
SLGL
Aug 20, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $78.58
Real-time Price: $66.01 info
Change: -$12.57 (-16%) info
Market Cap: $216.117M info
SLGL
Aug 11, 2026, 8:41 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $84.74
Real-time Price: $66.01 info
Change: -$18.73 (-22%) info
Market Cap: $216.117M info
SLGL
May 28, 2026, 8:01 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $71.40
Real-time Price: $66.01 info
Change: -$5.39 (-8%) info
Market Cap: $216.117M info
SLGL
May 28, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $71.40
Real-time Price: $66.01 info
Change: -$5.39 (-8%) info
Market Cap: $216.117M info